Navigation Links
Ambrilia Highlights Encouraging Data for its HIV Integrase,Inhibitor Program and Recent Developments at Annual Meeting

MONTREAL, QUEBEC--(CCNMatthews - June 14, 2007) - Ambrilia Biopharma Inc. (TSX:AMB), a biopharmaceutical company developing novel small molecules and peptides to treat infectious diseases and cancer, held its Annual General and Special Meeting today, during which the data reported yesterday on its novel series of HIV integrase inhibitors and recent developments were highlighted. The meeting was chaired by the new Chairman of the Board, Mr. Frederic Porte, and a progress report was presented by Mrs. Monique Letourneau, Executive Vice-President, Finance and Chief Financial Officer, followed by a scientific review presented by Dr. Bonabes de Rouge, Senior Executive Vice-President and Chief Scientific Officer.

"I would like to reiterate that the Board is committed to the success of Ambrilia. I look forward to guiding the Company as it continues to make advances in its key programs, and our productive relationship with Merck in the development of PPL-100", said Frederic Porte, Chairman of the Board of Ambrilia. "We are well advanced in the process of looking at strategic options for the Company and I believe this will enable us to be more focused as we move forward. Within the next number of months and even on into next year, our priorities will be the development of the HIV Integrase Program while bringing Octreotide and Goserelin closer to market", he concluded.

RECENT HIGHLIGHTS

- Ambrilia's novel series of HIV integrase inhibitors were presented at the prestigious XVI International HIV Drug Resistance Workshop. These preclinical data showed their potential distinct mechanism of action, which may lead to a different resistance profile from known integrase inhibitors currently in clinical development by pharmaceutical companies. The Company is now accelerating its HIV Integrase Inhibitor Program and aims to have a drug candidate within the next 12 months.

- Co-abstract on the structural
'"/>




Page: 1 2 3 4

Related medicine technology :

1. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
2. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
3. Expert Opinion Highlights Avigens AV411 as Potential New Therapeutic for Neuropathic Pain and Opioid Withdrawal
4. Positive Clinical Results for DG041 Lead Product Development Highlights at deCODE R&D Event
5. July Issue of Journal of Antimicrobial Chemotherapy Highlights Study of Factive Tablets for Five-Day Treatment of Community-Acquired Pneumonia
6. Inovio Biomedical Highlights Enhanced DNA Vaccine Potency with Electroporation DNA Delivery Technology and New Devices at Gene Therapy Meeting
7. Presentations at 2007 European Stroke Congress Highlights New Direction for Viprinex (ancrod)
8. Data to be Presented at ASCO 2007 Highlights sanofi-aventis Commitment to Cancer Care and Research
9. MedImmune Highlights Advances in Inflammatory Disease Pipeline With Series of Data Presentations
10. New Critical Path Report Highlights Research Needed to Foster Generic Drug Development
11. New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard Therapy in Treatment of Hypertension
Post Your Comments:
(Date:7/10/2014)... 11, 2014  Major advances in radiation therapy ... being highlighted in a three-day Oncology Summit taking ... July, 2014.  Renowned national and international cancer experts from ... and exchange knowledge on modern technologies making treatment ... The Summit will address a ...
(Date:7/10/2014)... 11. Juli 2014  Dilon Technologies, ... die molekulare Bildgebung, einschließlich molekularer Bildgebung ... CE-Zulassung für sein Navigator ® -Gamma-Sondensystem ... das Produkt jetzt europaweit vertreiben. Dilon ... der europäischen Länder ausgedehnt und bereits ...
(Date:7/10/2014)...  The U.S. Department of Health and Human Services ... (UH) Case Medical Center Seidman Cancer Center totaling $4.7 ... improving care for patients with complex cancer. ... a unique model developed at UH to enhance care ... or demonstrated need for high health care utilization.  ...
Breaking Medicine Technology:Improving quality and access to advanced cancer care in India and South Asia 2Improving quality and access to advanced cancer care in India and South Asia 3Improving quality and access to advanced cancer care in India and South Asia 4Improving quality and access to advanced cancer care in India and South Asia 5Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 3University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 4
... New to Antiretroviral Therapy Respond ... Similarly to Men and ... once-daily or twice-daily dosing of Abbott,s (NYSE:,ABT) protease inhibitor Kaletra(R) ... amount of HIV-1),and improving the immune system (increasing CD4 cells) ...
... a,biopharmaceutical company engaged in the discovery and development ... announced today,that Genentech, a collaborator, has moved a ... into a phase 1 clinical trial,that has begun ... and tolerability of both single and multiple doses ...
Cached Medicine Technology:Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines 2Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines 3Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines 4Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines 5Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines 6Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines 7Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines 8Tolerx Announces Achievement of Milestones upon anti-CD4 Antibody Program Advancement and Initiation of Phase 1 Clinical Trial 2Tolerx Announces Achievement of Milestones upon anti-CD4 Antibody Program Advancement and Initiation of Phase 1 Clinical Trial 3
(Date:7/10/2014)... 11, 2014 Karen Middleton, Executive Director ... CEO of Planned Parenthood of the Rocky Mountains (PPRM), ... Udall and Representative Diana DeGette were in Washington, DC ... Lobby decision and keeping bosses out of women’s birth ... to the president today in Denver addressing issues related ...
(Date:7/10/2014)... The Capital Institute for Neurosciences at ... procedure in a clinical trial that delivers chemotherapy to ... , During the procedure, done at Capital Health Medical ... threaded a tiny catheter through the patient’s femoral artery ... and into the brain. Once the catheter reached the ...
(Date:7/10/2014)... 3 fatty acids had healthier joints than those fed ... acids, according to Duke Medicine researchers. , The findings, ... (10.1136/annrheumdis-2014-205601) on July 11, 2014, suggest that unhealthy ... to worsening osteoarthritis. , "Our results suggest that dietary ... in the link between obesity and osteoarthritis," said Farshid ...
(Date:7/10/2014)... More than 200 experts on aggression, who ... violence, will attend the 21st World Meeting of the ... at the Loews Atlanta Hotel, July 15-19. , ... meeting, which is held every other year on alternating ... leading scholars from more than 20 different countries, which ...
(Date:7/10/2014)... Canada (PRWEB) July 10, 2014 ... account for an increasing number of accidents in ... in Safety Reboot. The articles highlight safety issues ... estimated 317 million accidents occur on the job ... Three features continue to explore "preventable workplace accidents." ...
Breaking Medicine News(10 mins):Health News:Naral Pro-Choice Colorado & Planned Parenthood Of The Rocky Mountains Statement On Udall & Degette Staying In Dc To Introduce Legislation 2Health News:New Trial Delivers Chemotherapy to Brain Tumor Through Artery in Leg 2Health News:New Trial Delivers Chemotherapy to Brain Tumor Through Artery in Leg 3Health News:Omega 3 fatty acids lessen severity of osteoarthritis in mice 2Health News:Georgia State Hosts National Conference On Aggression 2Health News:Georgia State Hosts National Conference On Aggression 3Health News:Georgia State Hosts National Conference On Aggression 4Health News:Safety Reboot Magazine Focuses on: Why Extended Hours is Dangerous in the Workplace; Why Custodial Work Can be Dangerous; and Improving Safety for Roofers 2Health News:Safety Reboot Magazine Focuses on: Why Extended Hours is Dangerous in the Workplace; Why Custodial Work Can be Dangerous; and Improving Safety for Roofers 3
... the Black Death as the world's worst pandemic if the ... get life prolonging drugs. The illness has killed 25 million ... infected each day with HIV, which destroys the immune system. ... will die, pushing the death toll beyond the 40 million ...
... suffer from asphyxia, which can lead to brain injury, multiple ... cent of babies who suffer from a moderate lack of ... no effective treatments to reduce the risk of asphyxia at ... a baby's temperature may have beneficial effects. ,UK researchers ...
... in the alpha gene are the cause of premature menopause ... about 2% of the total population. ,The University of ... of a genetic test, which would allow women// with a ... at risk. They analysed DNA from women who had experienced ...
... undergoing coronary artery bypass surgery is rising, even though ... artery bypass surgery uses a blood vessel from another ... or clogged arteries in the heart. A buildup of ... known as atherosclerosis. ,In the new study, ...
... FDA issued a statement about the potential for depression and ... reports say that the 15-year-old pilot who crashed his plane ... investigators don't know whether or not the teen, Charles J. ... death. Blood tests should reveal if the drug was in ...
... from the Institute of Health Sciences in Oxford found that ... likely to have a stillbirth, or to develop pre-eclampsia.// Taking ... the researchers. ,The researchers reviewed more than 23 ... benefits of anti-platelet drugs, of which low-dose aspirin is the ...
Cached Medicine News:
ThermalSeal RT (5mil) is Optically Clear for Real Time PCR and easy to apply. Works for all plates. Will not wrinkle in the freezer....
DMSO-resistant microplate sealing film...
Sealing tape featuring 3M adhesive technology. Opaque and strong. Prevents photo-degradation....
Aluminum Seal, Reflective, Bulk...
Medicine Products: